Home  |  Privacy Policy  |  Legal Notice  |  Contact Medical Information  |  Site Map
Top left rounded corner
Veletri Logo
Top right rounded corner

Survival Data in Idiopathic or Heritable Pulmonary Arterial Hypertension (IPAH/HPAH) at 12 weeks

Improved Survival in IPAH/HPAH patients

In a 12-week, open-label, randomized, parallel study, survival was improved in NYHA Functional Class III and IV IPAH/HPAH patients treated with epoprostenol plus conventional therapy as compared to patients treated with conventional therapy alone. Conventional therapy could include anticoagulants, oral vasodilators, diuretic agents, cardiac glycosides, and supplemental oxygen.1,2 The primary endpoint was a change from baseline in exercise capacity as measured by the 6-Minute Walk Test. Other major study objectives included the effect of epoprostenol on survival and quality of life (using the Chronic Heart Failure Questionnaire, the Nottingham Health Profile, and the Dyspnea-Fatigue Rating). The authors also evaluated the effects of epoprostenol on hemodynamics.1

Mortality Graph

At the end of the treatment (12 weeks)2:

  • None of the 41 patients receiving epoprostenol died
  • 8 of 40 (20%) patients receiving conventional therapy alone died (p=0.003)

No statistical difference in survival was observed in patients with PAH associated with scleroderma spectrum of diseases (PAH-SSD).

Read about dyspnea and fatigue data in IPAH/HPAH